In addition to tyrosine kinase inhibitors for EGFR‐mutated non‐small cell lung carcinoma, ADCs targeting EGFR have recently emerged as promising therapeutics for patients with HER‐positive cancers.177, 178, 179. Here, EGFR is linked to cancer.